Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 231

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 231
---
 to the Selling Shareholder as of the date of this prospectus, for sale by the Selling Shareholder pursuant to the Prior Registration Statement, without regard for the Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future share performance.

(2)The denominator is based on 11,816,721 common shares outstanding as of February 10, 2025, adjusted to include the issuance of the number of common shares set forth in the second column that we would have sold to the Selling Shareholder, assuming the average purchase price in the first column. The numerator is based on the number of common shares set forth in the second column.

(3)Represents the closing price of the common shares on the Nasdaq Capital Market on February 7, 2025, the last trading day prior to the date of the SEPA.

<div align='center'>152</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>SELLING SHAREHOLDER</div>

This prospectus relates to the offer and sale by the Selling Shareholder of up to 7,500,000 common shares that have been and may be issued by us to the Selling Shareholder under the SEPA. We are registering the common shares being offered by this prospectus pursuant to the provisions of the SEPA we entered into with the Selling Shareholder on February 10, 2025 in order to permit the Selling Shareholder to offer such shares for resale from time to time. Except for the transactions contemplated by the SEPA, and as set forth in the section entitled "Plan of Distribution" in this prospectus, the Selling Shareholder has not had any material relationship with us within the past three years. As used in this prospectus, the term "Selling Shareholder" means YA II PN, Ltd., a Cayman Islands exempt limited company, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling Shareholder's interest in the common shares other than through a public sale.

The table below presents information regarding the Selling Shareholder and the common shares that may be resold by the Selling Shareholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder and reflects holdings as of